Inventory Management
Procurement
Method Pay
Analytics & Reporting
Your formulary is a negotiation that already happened. Leadership picked the preferred products. The clinical board signed off on the equivalents. Procurement published the list. Suppliers agreed to the pricing.
On paper, every dollar of projected savings is already booked.
Then the orders go out…and most of those savings never show up in the P&L.
When you're dealing with dozens of locations, a formulary is only worth what your ordering system actually enforces.
Everything else is a suggestion. And suggestions, at scale, cost millions.
Your formulary is a preferred product list built on three criteria: economics, quality, and clinical fit. It reflects the products your organization has decided are the best value for the outcomes you need to deliver.
The word itself trips up some teams. After all, "Formulary" sounds clinical, but it's really just your approved buying list, whether you call it that or a preferred product catalog.
Leakage is what happens when the network doesn't buy from it.
These are far from acts of defiance. Rather, they’re just the natural, human behavior to go back toward the familiar and default.
Multiply that by hundreds of SKUs, dozens of locations, and thousands of orders per month. The negotiated discount looks excellent in the contract and disappears at the point of purchase.
The cost of leakage at enterprise DSO scale is measurable, and the numbers are ugly.
Method's data for elite DSOs identifies 15–25% cost variations between locations, driven in large part by formulary non-compliance. At 50+ locations, a 10% variance in supply spend across the network can represent millions of dollars annually in avoidable cost.
A healthy supply spend benchmark sits at 4–5% of collections. Anything north of 6% is a flashing indicator that something in your procurement process is broken, and the most common culprit at scale is a formulary nobody's enforcing.
That single number covers waste, off-price buying, and non-compliance all at once. It's the lagging indicator that tells you the upstream discipline isn't holding.
Then there's private label penetration.
Top-performing DSOs target 30–40% of total spend on private label products, which deliver 30–50% cost savings versus branded equivalents. Most DSOs sit closer to 20%. A DSO moving from 20% to 30–40% private label penetration can generate savings of hundreds of thousands to millions of dollars.
The gap between where your network sits and where it should sit is one of the cleanest EBITDA recovery opportunities available to a CFO right now, and it's almost entirely a formulary enforcement problem.
Manual processes that work at 3 locations stand no chance as more and more locations are added.
A procurement manager reviewing orders in a spreadsheet cannot catch off-formulary purchases in real time across a broad network without spending entire days doing just that.
By the time a variance shows up in a monthly report, the money is already spent, and the behavior is already a habit. The procurement team ends up in a constant state of retroactive coaching, flagging last month's problem while this month's problem is already happening.
This is the operational debt that compounds with every acquisition. Each new practice arrives with its own ordering habits, its own supplier relationships, and its own product preferences.
If your system can't absorb and standardize that practice in days, the integration window becomes a leakage window. You paid for the acquisition's forecasted margin, and then you watched the first ninety days of purchasing erode it.
The shift that protects margin at scale is the shift from monitoring to enforcement. That distinction matters. Monitoring tells you what has already happened. Enforcement changes what happens next.
When a formulary is built into the ordering interface itself, preferred products are visually flagged at the moment of purchase. Approved items show up first. Compliance percentages update in real time against the actual order.
When an off-formulary product is added to a cart, the order gets routed through an approval workflow instead of sliding through unchecked. Deviations become deliberate, visible, and tracked, which is what a formulary policy was supposed to produce in the first place.
The leverage compounds when leadership can update the formulary in seconds and have every location see the change instantly. If a better-priced clinical equivalent gets approved next Tuesday, every order placed after Tuesday reflects it.
That's the difference between a policy document and a system-enforced behavior.
Four numbers tell you whether your formulary is working at the network level:
While there are certainly more to track, these form the baseline any DSO procurement function should be able to produce on demand, at the network level, by location, and by SKU category.
The real cost of formulary non-compliance is the gap between the pricing your team negotiated and the pricing your network actually pays.
At enterprise organizations, that gap is where EBITDA goes to die—less in dramatic failures, but in thousands of small, individually reasonable ordering decisions that leadership never sees until the quarterly close.
Every dollar of leakage is multiple dollars you'd have to generate in new production to recover, and production dollars are harder to come by than procurement dollars.
Closing the compliance gap is the fastest margin lever available to an elite DSO right now, and it doesn't require renegotiating a single contract. It requires a system that turns the formulary you already built into the default behavior of every order, at every location, every time.
